This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): Imprime PGG, BTH1677, BTH 1677, BTH-1677
Description: Imprime PGG is a soluble/injectable beta 1,3/1,6 glucan derived from a proprietary strain of yeast (Saccharomyces cerevisiae). In the body, cells called macrophages engulf, digest and break down Imprime PGG into smaller components that subsequently bind to neutrophils, the most abundant immune cell in the body.
The Imprime PGG fragments bind to a receptor on the surface of neutrophils called Complement Receptor 3 (CR3), which primes the neutrophils for cancer cell killing through signaling events involving both SYK and PI 3-kinase. The primed neutrophils are now able to see cancer cells targeted with antibodies and complement as non-self, and kill them.
Biothera researchers discovered a predictive biomarker that identifies patients who are most likely to best respond to Imprime PGG. The biomarker is a naturally occurring antibody to beta glucan that is required for binding Imprime PGG to neutrophils and monocytes, the largest population of immune cells in the body. When bound, Imprime PGG engages and directs these innate immune cells to recognize and kill antibody-targeted cancer cells. Using a serum-based assay, Biothera is able to identify biomarker-positive patients.
Imprime PGG News
Additional information available to subscribers only: